IBDEI26X ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36777,1,4,0)
 ;;=4^C84.09
 ;;^UTILITY(U,$J,358.3,36777,2)
 ;;=^5001630
 ;;^UTILITY(U,$J,358.3,36778,0)
 ;;=C84.60^^169^1859^8
 ;;^UTILITY(U,$J,358.3,36778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36778,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
 ;;^UTILITY(U,$J,358.3,36778,1,4,0)
 ;;=4^C84.60
 ;;^UTILITY(U,$J,358.3,36778,2)
 ;;=^5001651
 ;;^UTILITY(U,$J,358.3,36779,0)
 ;;=C84.69^^169^1859^10
 ;;^UTILITY(U,$J,358.3,36779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36779,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,36779,1,4,0)
 ;;=4^C84.69
 ;;^UTILITY(U,$J,358.3,36779,2)
 ;;=^5001660
 ;;^UTILITY(U,$J,358.3,36780,0)
 ;;=C84.70^^169^1859^7
 ;;^UTILITY(U,$J,358.3,36780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36780,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
 ;;^UTILITY(U,$J,358.3,36780,1,4,0)
 ;;=4^C84.70
 ;;^UTILITY(U,$J,358.3,36780,2)
 ;;=^5001661
 ;;^UTILITY(U,$J,358.3,36781,0)
 ;;=C84.79^^169^1859^9
 ;;^UTILITY(U,$J,358.3,36781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36781,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,36781,1,4,0)
 ;;=4^C84.79
 ;;^UTILITY(U,$J,358.3,36781,2)
 ;;=^5001670
 ;;^UTILITY(U,$J,358.3,36782,0)
 ;;=C91.40^^169^1859^37
 ;;^UTILITY(U,$J,358.3,36782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36782,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,36782,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,36782,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,36783,0)
 ;;=C91.41^^169^1859^39
 ;;^UTILITY(U,$J,358.3,36783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36783,1,3,0)
 ;;=3^Hairy cell leukemia, in remission
 ;;^UTILITY(U,$J,358.3,36783,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,36783,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,36784,0)
 ;;=C91.42^^169^1859^38
 ;;^UTILITY(U,$J,358.3,36784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36784,1,3,0)
 ;;=3^Hairy cell leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,36784,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,36784,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,36785,0)
 ;;=C96.4^^169^1859^71
 ;;^UTILITY(U,$J,358.3,36785,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36785,1,3,0)
 ;;=3^Sarcoma of dendritic cells (accessory cells)
 ;;^UTILITY(U,$J,358.3,36785,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,36785,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,36786,0)
 ;;=C96.9^^169^1859^50
 ;;^UTILITY(U,$J,358.3,36786,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36786,1,3,0)
 ;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
 ;;^UTILITY(U,$J,358.3,36786,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,36786,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,36787,0)
 ;;=C90.00^^169^1859^58
 ;;^UTILITY(U,$J,358.3,36787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36787,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,36787,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,36787,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,36788,0)
 ;;=C90.01^^169^1859^57
 ;;^UTILITY(U,$J,358.3,36788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36788,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,36788,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,36788,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,36789,0)
 ;;=C90.02^^169^1859^56
 ;;^UTILITY(U,$J,358.3,36789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36789,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,36789,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,36789,2)
 ;;=^5001753
